Driehaus Capital Management LLC Immunovant, Inc. Transaction History

Driehaus Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $723,800 - $1.3 Million	-77,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $9.24 Million - $35 Million	-706,651 Reduced 90.17%	77,000 $1.24 Million
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $1.49 Million - $2.16 Million	-41,054 Reduced 4.98%	783,651 $36.2 Million
Q3 2020 Nov 16, 2020	SELL	$22.61 - $38.9 $1.04 Million - $1.79 Million	-45,899 Reduced 5.27%	824,705 $29 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $3.62 Million - $7.43 Million	261,205 Added 42.86%	870,604 $21.2 Million
Q1 2020 May 15, 2020	SELL	$8.36 - $17.13 $101,206 - $207,375	-12,106 Reduced 1.95%	609,399 $9.49 Million
Q4 2019 Feb 12, 2020	BUY	$10.02 - $16.4 $6.23 Million - $10.2 Million	621,505 New	621,505 $9.85 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.